Atezolizumab is a humanized monoclonal antibody utilized as an immunotherapy in the treatment of some cancers including non-small cell lung cancer, urothelial carcinoma, and other tumors. The antibody works by blocking the PD-L1 ligand from binding to its PD-1 receptor, thereby releasing the brakes on the body’s immune response against cancer cells. It has fewer side effects compared to chemotherapy and is more effective for cancers which are difficult to treat with other modalities.
The global atezolizumab market is estimated to be valued at US$ 308 million in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period from 2023 to 2030.
Key Takeaways
Key players: Key players operating in the atezolizumab market are Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Key opportunities: The advancement of cancer immunotherapy has created viable treatment options for late-stage cancers. Ongoing clinical trials evaluating atezolizumab’s efficacy in new indications are expected to widen the drug’s label. Combination therapies with atezolizumab and other immunotherapies or chemotherapy hold significant potential to improve patient outcomes.
Technological advancements: Developments in cancer biologics have revolutionized the disease management landscape. Atezolizumab harnesses the power of the immune system by inhibiting the PD-L1/PD-1 immune checkpoint. Continued R&D is being conducted to enhance the drug’s mechanism of action, dosing regimen, and to develop novel formulation approaches for improved delivery.
Market drivers
The increasing incidence and prevalence of cancer globally is a major factor driving the growth of the atezolizumab market. As per estimates, over 18 million new cancer cases were reported worldwide in 2020. Atezolizumab shows enhanced efficacy and improved safety compared to standard of care therapies. This, coupled with rising demand for personalized treatment approaches, is boosting the adoption of cancer immunotherapies including atezolizumab. Moreover, growing access to health insurance and favorable government initiatives are helping more patients opt for high-cost biologic drugs.
Challenges in the market
The Atezolizumab market is facing various challenges such as high research and development cost involved in development of biologics, stringent regulations for approval of biosimilars and biologics, and risk of drug failure during clinical trials. Other challenges include patent expiration of blockbuster drugs resulting in increased competition and pricing pressure.
SWOT Analysis
Strength: High targeted therapeutic efficacy with fewer side effects. Weakness: High development and production costs. Opportunity: Increasing demand for effective cancer treatment drugs. Threats: Entry of affordable biosimilars post patent expiry and stringent regulations.
Geographically, North America dominated the Atezolizumab market in terms of value in 2022 due to growing cancer patient base and rising healthcare expenditure. Asia Pacific is expected to be the fastest growing regional market between 2023-2030, attributed to increasing patient awareness, healthcare reforms, and rising research activities.
The United States accounted for the major share of the global Atezolizumab market in terms of value in 2022 and is expected to maintain its leading position during the forecast period. This is attributed to the increasing cancer prevalence, rising healthcare expenditure, availability of advanced healthcare facilities, and favorable reimbursement scenario in the country.
Europe held the second largest share of the global Atezolizumab market in 2022 due to advanced healthcare infrastructure coupled with growing R&D activities in major European countries including Germany, United Kingdom, and France.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
